Literature DB >> 24562810

Liposomal co-delivery of omacetaxine mepesuccinate and doxorubicin for synergistic potentiation of antitumor activity.

Gayong Shim1, Sangbin Lee, Junhyeok Choi, Soondong Lee, Chan-Wha Kim, Yu-Kyoung Oh.   

Abstract

PURPOSE: Anticancer chemotherapy usually involves the administration of several anticancer drugs that differ in their action mechanisms. Here, we aimed to test whether the combination of omacetaxine mepesuccinate (OMT) and doxorubicin (DOX) could show synergism, and whether the liposomal co-delivery of these two drugs could enhance their antitumor effects in cervical carcinoma model.
METHOD: OMT-loaded liposomes (OL) were prepared by loading the drug in the lipid bilayers. OL were then electrostatically complexed with DOX, yielding double-loaded liposomes (DOL). DOX-loaded liposomes (DL) were formulated by electrostatic interaction with negatively charged empty liposomes (EL). The combination index (CI) values were calculated to evaluate the synergism of two drugs. In vitro antitumor effects against HeLa cells were measured using CCK-8, calcein staining, and crystal violet staining. In vivo antitumor effects of various liposomes were tested using HeLa cell-bearing mice.
RESULTS: Combination of DOX and OMT had ratio-dependent synergistic activities, with very strong synergism observed at a molar ratio of 4:1 (DOX:OMT). The sizes of EL, DL, OL, and DOL did not significantly differ, but the zeta potentials of DL and DOL were slightly higher than those of OL and EL. In vitro, DOL showed higher antitumor activity than OL, DL or EL in cervical carcinoma HeLa cells. In vivo, unlike other liposomes, DOL reduced the tumor growths by 98.6% and 97.3% relative to the untreated control on day 15 and 25 after the cessation of treatment, respectively.
CONCLUSIONS: These results suggest that liposomal co-delivery of DOX and OMT could synergistically potentiate antitumor effects.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24562810     DOI: 10.1007/s11095-014-1317-3

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  39 in total

1.  Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer.

Authors:  Daniel Chan; Yun Zheng; Jeffrey W Tyner; Wee Joo Chng; Wen Wen Chien; Sigal Gery; Geraldine Leong; Glenn D Braunstein; H Phillip Koeffler
Journal:  J Cancer Res Clin Oncol       Date:  2013-07-04       Impact factor: 4.553

Review 2.  Omacetaxine as an anticancer therapeutic: what is old is new again.

Authors:  Meir Wetzler; David Segal
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

3.  Suppression of myeloid cell leukemia-1 (Mcl-1) enhances chemotherapy-associated apoptosis in gastric cancer cells.

Authors:  Hideko Akagi; Hajime Higuchi; Hidetoshi Sumimoto; Toru Igarashi; Ayano Kabashima; Hiroyuki Mizuguchi; Motoko Izumiya; Gen Sakai; Masayuki Adachi; Shinsuke Funakoshi; Shoko Nakamura; Yasuo Hamamoto; Takanori Kanai; Hiromasa Takaishi; Yutaka Kawakami; Toshifumi Hibi
Journal:  Gastric Cancer       Date:  2012-04-24       Impact factor: 7.370

4.  Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance.

Authors:  Kirsteen J Campbell; Mary L Bath; Marian L Turner; Cassandra J Vandenberg; Philippe Bouillet; Donald Metcalf; Clare L Scott; Suzanne Cory
Journal:  Blood       Date:  2010-07-14       Impact factor: 22.113

5.  The plant alkaloid and anti-leukemia drug homoharringtonine sensitizes resistant human colorectal carcinoma cells to TRAIL-induced apoptosis via multiple mechanisms.

Authors:  Lenka Beranova; Antonio R Pombinho; Jarmila Spegarova; Michal Koc; Magdalena Klanova; Jan Molinsky; Pavel Klener; Petr Bartunek; Ladislav Andera
Journal:  Apoptosis       Date:  2013-06       Impact factor: 4.677

6.  Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells.

Authors:  H M Aliabadi; P Mahdipoor; H Uludağ
Journal:  Cancer Gene Ther       Date:  2013-03-01       Impact factor: 5.987

7.  Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells.

Authors:  Sun-Mi Yun; Kyung Hee Jung; Hyunseung Lee; Mi Kwon Son; Ju-Hyeon Seo; Hong Hua Yan; Byung Hee Park; Sungwoo Hong; Soon-Sun Hong
Journal:  Cancer Lett       Date:  2013-01-20       Impact factor: 8.679

8.  Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer.

Authors:  J Crown; M J Kennedy; P Tresca; M Marty; M Espie; H A Burris; M DeSilvio; M R Lau; D Kothari; K M Koch; V Diéras
Journal:  Ann Oncol       Date:  2013-08       Impact factor: 32.976

9.  Overexpression of Mcl-1 confers multidrug resistance, whereas topoisomerase IIβ downregulation introduces mitoxantrone-specific drug resistance in acute myeloid leukemia.

Authors:  David L Hermanson; Sonia G Das; Yunfang Li; Chengguo Xing
Journal:  Mol Pharmacol       Date:  2013-05-21       Impact factor: 4.436

Review 10.  Nano-sized polymers and liposomes designed to deliver combination therapy for cancer.

Authors:  Anat Eldar-Boock; Dina Polyak; Anna Scomparin; Ronit Satchi-Fainaro
Journal:  Curr Opin Biotechnol       Date:  2013-05-29       Impact factor: 9.740

View more
  3 in total

Review 1.  Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine.

Authors:  Samuel S Linton; Samantha G Sherwood; Kelly C Drews; Mark Kester
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2015-07-07

Review 2.  Strategies for Liposome Drug Delivery Systems to Improve Tumor Treatment Efficacy.

Authors:  Jia Wang; Junbo Gong; Zhenping Wei
Journal:  AAPS PharmSciTech       Date:  2021-12-14       Impact factor: 3.246

Review 3.  Cephalotaxus Alkaloids.

Authors:  Joëlle Pérard-Viret; Laith Quteishat; Rana Alsalim; Jacques Royer; Françoise Dumas
Journal:  Alkaloids Chem Biol       Date:  2017-08-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.